Abstract: |
Although an excellent radionuclide for application to systemic isotopic therapy when complexed to various monoclonal antibodies, the lack of photon emission from yttrium-90 makes the determination of the pharmacokinetics and dosimetry of the resultant radiopharmaceutical difficult. The introduction of the positron-emitting radionuclide yttrium-86 (T-1/2 = 14.7 h, beta(+) = 33%) provides the non-invasive quantitation for the biodistribution of the chelated complex. The yttrium-86 radionuclide is produced at Memorial Sloan-Kettering using the CS-15 cyclotron via the (p,n) nuclear reaction on an enriched strontium-86 target. The separation is effectively achieved through a combination of solvent extraction and ion exchange chromatography. Once investigational new drug approval has been received, the mixed nuclides, Y-90 and Y-86, are to be used to formulate the HuM195 labeled monoclonal antibody, a radiopharmaceutical under active investigation against hematopoietic progenitor cells. |